Form 4: Pulse Biosciences Director Granted Stock Options

Pulse Biosciences Director Richard van den Broek was granted 30,000 stock options with a $16.16 exercise price, vesting monthly over one year.

Summary

• Director Richard van den Broek of Pulse Biosciences, Inc. (PLSE) was granted 30,000 stock options.
• The stock options have an exercise price of $16.16 per share.
• The grant date for these options was August 15, 2025.
• The options will vest in equal monthly installments over a one-year period, with the first installment occurring on September 15, 2025.
• Vesting is contingent on Mr. van den Broek's continued service to the company.
• The stock options are set to expire on August 15, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management and shareholder interests, incentivizing long-term performance. It's a routine compensation event, not indicative of extraordinary news, hence a neutral-to-slightly positive score.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The one-year monthly vesting schedule encourages the director's continued service and commitment to the company's success.

Negatives

• No immediate negatives are apparent from this routine stock option grant.

Risks

• The vesting of the 30,000 stock options is subject to the reporting person's continued service through each vesting date, meaning unvested options could be forfeited if service ceases.

Future Outlook

The stock options are designed to vest over a one-year period, contingent on the director's continued service, indicating an expectation of ongoing commitment and alignment with the company's long-term objectives.

Management Comments

• The grant of stock options to Director Richard van den Broek is consistent with the company's established compensation practices for its board members, aiming to align their incentives with long-term shareholder value.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and medical device industries, where Pulse Biosciences operates, to align executive and board interests with long-term shareholder value and incentivize performance.

Comparison to Industry Standards

• The grant of stock options to a director with a vesting schedule is a common and standard practice for publicly traded companies, particularly within the biotechnology and medical device sectors, to incentivize long-term performance and align director interests with shareholder value.
• While specific comparable companies or projects are not detailed in this filing, this compensation structure is widely observed across the industry.

Related Party Transactions

• The grant of 30,000 stock options to Director Richard van den Broek constitutes a related-party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of the director's interests with long-term shareholder value creation.
• Management: The director's compensation structure is clarified, reinforcing their commitment to the company.

Next Steps

• Monthly vesting of the 30,000 stock options will occur over a one-year period, starting September 15, 2025.
• The director may exercise the vested options at any time before their expiration date of August 15, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director, which is a standard practice to align interests. It does not contain information that would fundamentally alter the investment thesis for Pulse Biosciences, nor does it signal significant operational or financial changes. Therefore, a 'Hold' recommendation is appropriate as this filing alone does not provide a basis for a change in investment strategy.

Keywords

Pulse Biosciences, PLSE, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant